Mayo Clinic | Strategic Alliance Partners

Talal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses the rising incidence of colorectal cancer (CRC).

Tanios Bekaii-Saab, MD, discusses ways to further develop precision medicine within the treatment of patients with gastrointestinal cancers.

Matthew P. Goetz, MD, chair of the Breast Cancer Disease-Oriented Group and co-leader of the Women’s Cancer Center at the Mayo Clinic, discusses survival data with CDK4/6 inhibitors in patients with hormone receptor-positive breast cancer.

Investigators are taking a personalized approach to treating patients with multiple myeloma by introducing novel agents in combination with backbone chemotherapies, based on patients’ individual genetic profiles.

Matthew P. Goetz, MD, discusses the impact of CDK4/6 inhibitors and their future role in the treatment of hormone receptor–positive breast cancer.

Pashtoon M. Kasi, MD, MBBS, MS, an assistant professor of Oncology and senior associate consultant in the Division of Hematology/Oncology, Mayo Clinic, discusses treatment approaches for patients with metastatic colorectal cancer.

Study results demonstrate that men and women differ in their immunological responses to foreign and self-antigens.

Kimberly S. Corbin, MD, radiation oncologist at the Mayo Clinic, discusses patient selection for proton therapy in breast cancer.

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses emerging therapies for the treatment of patients with triple-negative breast cancer (TNBC).

Pashtoon M. Kasi, MD, MBBS, MS, discusses advances and unmet needs in metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses resistance to targeted therapy in the treatment of patients with colorectal cancer.

Kimberly S. Corbin, MD, sheds light on the use of proton radiation therapy in the breast cancer space and which patients may benefit from this approach.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the challenges of bringing a precision medicine approach into the clinic in colorectal cancer.

Ciara O’Sullivan, MB, BCh, discusses the need for treatment de-escalation for patients with HER2-positive breast cancer, as well as the challenges that remain in tailoring treatment.

Oscar J. Manrique, MD, discusses the current treatments for patients with lymphedema who have breast cancer and the challenges that remain in this space.

Judy C. Boughey, MD, discusses the surgical management of the axilla in patients with node-positive breast cancer and less invasive approaches for disease management.

Roberto A. Leon Ferre, MD, oncologist, Mayo Clinic, discusses ongoing research in triple-negative breast cancer (TNBC).

Judy C. Boughey, MD, chair, Division of Surgery Research, Mayo Clinic, discusses the surgical management of patients with node-positive breast cancer.

Ciara O'Sullivan, MB, BCh, senior associate consultant, assistant professor of oncology, Division of Medical Oncology, Department of Oncology, Mayo Clinic, discusses the future for HER2-positive breast cancer treatment.

Kabir Mody, MD, medical oncologist, Mayo Clinic, discusses treatment options for patients with hepatocellular carcinoma.

Tanios Bekaii-Saab, MD, medical oncologist, Mayo Clinic, discusses the utility of next-generation sequencing in metastatic colorectal cancer (mCRC).

Kathryn Ruddy, MD, associate professor of Oncology, Mayo Clinic, discusses the management of central nervous system (CNS) metastases in HER2-positive breast cancer.

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses the evolving role of chemotherapy in the treatment of bladder cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the use of TAS-102 (Lonsurf) and regorafenib (Stivarga) in patients with metastatic colorectal cancer (mCRC).

Thai H. Ho, MD, PhD, assistant professor of medicine, Mayo Clinic, discusses the management of immune-related adverse events in the treatment of kidney cancer.

Tanios Bekaii-Saab, MD, discusses the ReDOS and IMblaze370 trials with regorafenib trials in metastatic colorectal cancer.

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses regorafenib (Stivarga) use in metastatic colorectal cancer (mCRC).

Stephen M. Ansell, MD, PhD, discusses overcoming immune evasion in lymphoma.

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses the role of PD-1 blockade in lymphoma.